Advertisement

Combined Proctectomy and Hepatectomy for Metastatic Rectal Cancer Should be Undertaken with Caution: Results of a National Cohort Study

  • Seth J. ConcorsEmail author
  • Charles M. Vining
  • Nicole M. Saur
  • Robert E. Roses
  • Emily Carter Paulson
Colorectal Cancer

Abstract

Background

Simultaneous proctectomy and hepatic resection for stage IV rectal cancer remains controversial due to concerns for increased morbidity and mortality. While small series have described simultaneous rectal and hepatic resection, surgical outcomes in a large national cohort have not been described.

Methods

Overall, 9012 patients with stage IV rectal adenocarcinoma with hepatic metastases were identified in the National Cancer Data Base (2010–2015). Associations between treatment selection, tumor and patient characteristics, 30- and 90-day mortality, and factors predictive of survival after surgery were examined. Logistic regression analyses were used to evaluate associations between tumor/patient characteristics, and selection of combined proctectomy and hepatectomy (C-PH). Kaplan–Meier analysis was used to identify median survival stratified by age and other patient-specific factors.

Results

Among patients included for analysis, 1331 (14.8%) underwent C-PH. Factors associated with lower rates of C-PH included increasing age, Black/Hispanic race, increased Charlson comorbidity score, Medicare/Medicaid/uninsured status, and treatment at a community cancer program. Thirty- and 90-day mortality increased with age (Chi square 11.4, p < 0.005; and Chi square 23.9, p < 0.001, respectively). On multivariate analysis, poorer survival after C-PH was associated with age > 70 years (hazard ratio [HR] 1.8, 95% confidence interval [CI] 1.0–2.5, p < 0.001), perineural invasion (HR 1.5, 95% CI 1.2–1.9, p < 0.001), kras mutation (HR 1.5, 95% CI 1.1–2.1, p = 0.006), positive circumferential margin (HR 1.3, 95% CI 1.0–1.7, p = 0.03), and omission of postoperative chemotherapy (HR 1.4, 95% CI 1.1–1.7, p = 0.002).

Conclusions

C-PH should be utilized with caution in frail, high-risk patients. Such patients may be better served by staged surgical management or nonsurgical therapy.

Notes

Disclosures

The authors have no conflict of interest.

Supplementary material

10434_2019_7497_MOESM1_ESM.docx (1.1 mb)
Supplementary material 1 (DOCX 1094 kb)

References

  1. 1.
    American Cancer Society. Cancer facts and figures 2018. Atlanta, GA: American Cancer Society; 2018.Google Scholar
  2. 2.
    Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A-M. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.CrossRefGoogle Scholar
  3. 3.
    Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.CrossRefGoogle Scholar
  4. 4.
    National Comprehensive Cancer Network. NCCN Guidelines Rectal Cancer. National Comprehensive Cancer Network; 2018.Google Scholar
  5. 5.
    Hamed OH, Bhayani NH, Ortenzi G, Kaifi JT, Kimchi ET, Staveley-O’Carroll KF, et al. Simultaneous colorectal and hepatic procedures for colorectal cancer result in increased morbidity but equivalent mortality compared with colorectal or hepatic procedures alone: outcomes from the National Surgical Quality Improvement Program. HPB (Oxford). 2013;15(9):695–702.Google Scholar
  6. 6.
    Tzeng C-WD, Cooper AB, Vauthey J-N, Curley SA, Aloia TA. Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients. HPB (Oxford). 2014;16(5):459–68.Google Scholar
  7. 7.
    Silberhumer GR, Paty PB, Temple LK, Araujo RLC, Denton B, Gonen M, et al. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. Am J Surg. 2015;209(6):935–42.CrossRefGoogle Scholar
  8. 8.
    Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The national cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.CrossRefGoogle Scholar
  9. 9.
    International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World Health Organization; 2013.Google Scholar
  10. 10.
    StataCorp. College Station, TX: StataCorp LLC; 2017.Google Scholar
  11. 11.
    Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer. Cancer. 2007;109(4):718–26.CrossRefGoogle Scholar
  12. 12.
    Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases. Cancer. 2009;115(4):752–9.CrossRefGoogle Scholar
  13. 13.
    Shahrokni A, Alexander K. The age of talking about age alone is over. Ann Surg Oncol. 2019;26(1):12–14.CrossRefGoogle Scholar
  14. 14.
    Gosens MJEM, Klaassen RA, Tan-Go I, Rutten HJT, Martijn H, van den Brule AJC, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal Carcinoma. Clin Cancer Res. 2007;13(22):6617–23.CrossRefGoogle Scholar
  15. 15.
    van Gijn W, Gooiker GA, Wouters MW, Post PN, Tollenaar RA, van de Velde CJ. Volume and outcome in colorectal cancer surgery. Eur J Surg Oncol. 2010;36 Suppl 1:S55–63.CrossRefGoogle Scholar
  16. 16.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.CrossRefGoogle Scholar
  17. 17.
    Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Nat Cancer Inst. 2002;94(5):334–57.CrossRefGoogle Scholar
  18. 18.
    Breen N, Lewis DR, Gibson JT, Yu M, Harper S. Assessing disparities in colorectal cancer mortality by socioeconomic status using new tools: health disparities calculator and socioeconomic quintiles. Cancer Causes Control. 2017;28(2):117–25.CrossRefGoogle Scholar
  19. 19.
    Schulman KA, Berlin JA, Harless W, Kerner JF, Sistrunk S, Gersh BJ, et al. The effect of race and sex on physicians’ recommendations for cardiac catheterization. N Engl J Med. 1999;340(8):618–26.CrossRefGoogle Scholar
  20. 20.
    Werner RM, Asch DA, Polsky D. Racial profiling. Circulation. 2005;111(10):1257–63.CrossRefGoogle Scholar
  21. 21.
    Esnaola NF, Ford ME. Racial differences and disparities in cancer care and outcomes: where’s the rub? Surg Oncol Clin N Am. 2012;21(3):417–37.CrossRefGoogle Scholar
  22. 22.
    Shaw JJ, Santry HP, Shah SA. Specialization and utilization after hepatectomy in academic medical centers. J Surg Res. 2013;185(1):433–40.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of SurgeryHospital of the University of PennsylvaniaPhiladelphiaUSA
  2. 2.Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Department of SurgeryCorporal Michael J. Crescenz VA Medical CenterPhiladelphiaUSA

Personalised recommendations